



Quarterly Report

First Quarter 2025

About iZafe Group

iZafe Group is a Life-Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management in the home.

The company leads the development of digital drug dispensing through the pharmaceutical robot Dosell and the digital dosett device Pilloxa. The company's solutions reduce the risk of incorrect medication in the home, relieve the burden on public healthcare, increase the quality of life and create a safer environment for relatives.



Financial Performance in Summary


- ✓ Total net revenue for the quarter amounted to 1,318 TSEK (3,410), now primarily consisting of recurring license revenues. This contrasts with the same period last year, when revenue was mainly driven by hardware sales, which in turn enable the generation of these recurring license revenues.
- ✓ Operating result (EBIT) for the quarter amounted to -3,519 TSEK (-5,569).
- ✓ Operating result before depreciation and amortization (EBITDA) for the quarter amounted to -2,538 TSEK (-4,588), a clear improvement despite lower revenue compared to the same period last year. This reflects a more profitable revenue mix and increased operational efficiency.
- ✓ Result after financial items for the quarter amounted to -3,779 TSEK (-5,609).
- ✓ Cash flow from operating activities for the quarter amounted to -7,013 TSEK (-4,109).
- ✓ Earnings per share for the quarter before/after dilution amounted to -0.01 SEK (-0.02).
- ✓ Equity per share at the end of the period amounted to 0.04 SEK (0.08).
- ✓ The equity ratio at the end of the period was 53.2% (67.5%).

Significant events during the quarter

- ✓ iZafe Group has completed a directed share issue of approximately SEK 9.2 million through the issuance of 46.15 million B-shares at a subscription price of SEK 0.20 per share. The capital will be used to strengthen working capital, accelerate growth, and support the expansion of Dosell and Pilloxa into new markets.
- ✓ iZafe Group AB has initiated the sales of Dosell in Spain through its partnership with Ti-Medi. The product is launched under the Savioo Home brand and is now available through Ti-Medi's network of over 1,500 pharmacies. Dosell enables automatic reminders and alerts in case of missed medication, improving adherence and safety for patients and their families. The launch marks an important milestone in iZafe Group's international expansion.
- ✓ iZafe Group AB has entered into an agreement with Carnegie Investment Bank AB as its new Certified Adviser. Carnegie will assume the role on April 1, 2025, and until then, Mangold Fondkommission AB will continue to serve as the company's Certified Adviser.

Significant events after the end of the quarter

- ✓ iZafe Group AB has continued to grow during the quarter with an increase in billable Dosell units and strong demand in Sweden, the Netherlands, and Spain. Three new municipalities have initiated operations, the partner TCCN is launching Dosell TV in the Netherlands, and over 50 pharmacies in Spain have joined the Savioo Home concept. The company is experiencing growing commercial momentum and is engaged in discussions with new partners for continued expansion.




Comments from CEO



2025 has started strong for iZafe Group, and we are now entering the next phase of our growth journey. We can clearly see how previous deliveries of Dosell to our partners are now bearing fruit in the form of recurring license revenues – the most profitable part of our business model. Our focus on scalability, recurring revenues, and international expansion is beginning to show tangible financial results.

During the first quarter, the number of active Dosell units has continued to grow rapidly. It is now – as these units are activated and used daily – that we are realizing the value of the investments and deliveries made throughout 2024. Our ARR at the end of the quarter surpassed 3 MSEK, confirming that we are on track to meet our financial targets for the year. This development is fully in line with the growth forecast we presented in the previous quarterly report and clearly shows that our business model is scaling as expected.



The shift towards recurring revenues improves profitability

Even though net revenue in Q1 2025 (1.3 MSEK) is lower than the corresponding quarter last year, the result has improved significantly. This is thanks to a larger share of revenues now being license-based with high margins – a direct effect of the increased activation rate among our partners. Operating profit improved by more than 2 MSEK compared to Q1 2024, providing clear evidence that our strategy is working.

We have now established a recurring revenue model that is scalable, predictable, and profitable. As more Dosell units are activated, revenues grow without a corresponding increase in the cost base – a powerful shift that lays the foundation for cash flow positivity and long-term profitability.

Momentum across multiple markets

During Q1, we have continued to increase our presence and demand in our key markets:

- **Sweden:** We have now launched Dosell in 14 new municipalities so far this year, with several more in the pipeline. An increasing number of municipalities are moving from pilot projects to full implementation, demonstrating that we have found the right fit in both product and offering. Demand is driven by safety, simplicity, and increased efficiency in home care services.

- **Netherlands:** Our partner TCCN has reported continued strong activation rates, including 72 units delivered to their customer MobileCare during March. The launch of Dosell TV and exposure at trade fairs are creating additional momentum. The Netherlands is now a mature growth market for us.

- **Spain:** Our Spanish partner Ti-Medi has officially launched Dosell as part of its Savioo platform. Over 50 pharmacies have already joined the concept. This gives us access to a rapidly growing market with a high proportion of dose pouch users and strong demand for digital solutions.

Comments from CEO

Strengthened liquidity after the end of the quarter

At the end of the quarter, cash and cash equivalents amounted to approximately 0.7 MSEK, reflecting the investments we have made to accelerate our expansion. However, it is important to highlight that half of the previously communicated directed share issue of approximately 9.2 MSEK was received by the company in April. This means that our cash position has been significantly strengthened after the period, creating better conditions to continue executing our growth plan.

Focus on real impact – and what truly matters

We now have strong momentum in the business, with the number of Dosell units loaded with medication and dispensing daily increasing month by month. This development forms the foundation for both our long-term growth and the societal benefit we aim to deliver.

Our most important key metric is not simply how many units we have sold or are billing licenses for, but how many times we have ensured correct medication. So far, we have surpassed over 400,000 doses dispensed at the right time – each dose representing a moment of safety for the user, reduced strain on healthcare providers, and improved adherence.

A new phase – moving full speed ahead

In a short time, we have established a product that is in demand, a scalable business model, and a clear growth strategy. During the quarter, we have further improved the product with a new software version, maintained our cost focus, and strengthened our customer relationships. The momentum we now see – both in actual usage and business development – is clear evidence that something has shifted.

In parallel, we continue to engage in discussions with new potential partners, both in existing and new markets, with the aim of expanding our presence and reaching more patients through the right local collaborations.

We are entering a breakthrough year where the focus is on continuing to scale, streamline operations, and create value – for our users, partners, society, and our shareholders.

Thank you to all employees, partners, and shareholders who make this journey possible.



Stockholm in April 2025

Anders Segerström

Chief Executive Officer, iZafe Group



Company overview

Addressing an Aging Population

An rapidly aging population and a significant increase in chronic health conditions are increasing the risk of medication errors. A growing number of people are being prescribed medications, and up to 70 percent of those over 60 years old take three or more medications, just in Europe alone. Demographically, there are clear changes occurring where the population over 65 years old is projected to increase from around 21 percent of the total population in 2022 to over 24 percent by 2030. This is happening alongside the growing challenge of ensuring an adequate quantity and quality of workforce in home healthcare. Studies indicate that it will be necessary to introduce digital aids to manage the changing conditions that healthcare is facing.

Improving Health Through Correct Medication

Within the EU, poor medication adherence results in 200,000 deaths annually, costing society 125 billion Euros. iZafe Group develops and commercializes digital products and services that ensure people take the right medication at the right time. iZafe Group's patented product, Dosell, is a digital medication dispensing robot specially designed to ensure medication adherence. With Dosell, conditions are created for more individuals to lead healthier and more independent lives. iZafe Group also markets and sells the connected pillbox, Pilloxa, along with its accompanying mobile application, which serves the same purpose as Dosell by ensuring medication adherence. Pilloxa currently targets a different demographic primarily comprised of pharmaceutical companies.

A Growing Market

Digital platforms enable people to receive care where and when it's needed, reducing the risks of medication errors and enabling more personalized care. By the end of 2022, globally, 4.4 million connected devices were being used to ensure medication adherence. This market is expected to grow at an annual growth rate of 13.2 percent over the coming years, reaching 8.2 million units by 2027. According to a recent report from 2023 conducted by Berg Insight, the market for connected medication management solutions offers growth opportunities for companies in the industry. The industry is expected to grow from a value of USD 4.6 billion to USD 8.4 billion by 2027. By deploying the right welfare technology, patients can live more independently in their own homes, while healthcare resources can be allocated more favorably. A medication robot can thus ensure that the user receives the right medication at the right time, allowing caregivers or home service visits to focus on tasks other than medication management.

Digitalization Ensures Efficient and Patient-Safe Care

iZafe's product Dosell enables welfare and healthcare resources to be used more efficiently by automating processes that would otherwise consume time; time that could be better spent on other forms of care than medication management. Dosell is designed to be used by the patient at home, in healthcare settings, or in elderly care. Dosell dispenses medication pouches to the patient at specified times indicated on the pouch. At the same time, a caregiver, relative, or friend can be connected to the Dosell unit via a mobile app or alarm platform to monitor adherence and whether the patient has taken their medication at the specified time. If, for example, a medication has not been taken, an alert is sent to the caregiver or a relative. This results in increased patient safety and greater independence for the patient. In Sweden, over 280,000 people currently use medication pouches according

to the eHealth Authority, and this number is expected to grow as the population ages. The smart pillbox developed by Pilloxa also ensures adherence and provides data for patients who do not receive their medications in pouches but still need a tool to ensure the right medication at the right time. Together with Dosell, Pillbox, and mobile applications, iZafe can ensure adherence throughout the patient journey.

Business model

iZafe Group's products and services are sold through selected corporate partners with local market knowledge. iZafe Group receives recurring revenue in the form of license fees from sales to public and private welfare and healthcare partners, as well as subscription fees from sales to consumers. In addition to recurring revenue, a hardware cost is charged for each Dosell and Pillbox. B2B sales target partners who develop and sell digital welfare and healthcare platforms. This means that iZafe Group does not need to build a large sales organization but can leverage the expertise of its respective partners. B2C sales currently take place on Dosell's own website for the Swedish consumer market. In markets outside of Sweden, B2C sales are to be conducted through partners offering integrated welfare and healthcare solutions directly to consumers.

Increasing Partnership Distribution and Rising B2C Interest

iZafe Group currently has partners committed in eight countries in Europe. The growing interest in the Dosell medication robot is evident, and several additional entities are interested in the opportunity to sell Dosell. The focus will continue to be on ensuring quality-assured implementation, training, support, and delivery in line with increased volumes. The company sees an increased interest in being able to ensure medication adherence independently and safely.

Dosell consolidates its position in the European market.

One of iZafe Group's central focus areas has been to ensure that Dosell meets the needs of both partners and patients. The primary focus for the upcoming period will be to ensure high-quality delivery and implementation in line with the commitments of our partners as previously communicated. Furthermore, iZafe will continue to work on identifying growth opportunities through acquisitions, new partnerships, and further development and commercialization of products and services with partners to facilitate more patients in getting the right medication at the right time.



Key figures

THE GROUP

	2025	2024	2024
TSEK	Jan-Mar	Jan-Mar	Jan-Dec
Net sales	1 318	3 410	7 954
Operating result (EBIT)	-3 519	-5 569	-19 425
Operating result before depreciation and amortization (EBITDA)	-2 538	-4 588	-15 495
Profit after financial items (EBT)	-3 779	-5 609	-20 509
Earnings per share before/after dilution, SEK	-0,01	-0,02	-0,08
Equity per share, SEK	0,04	0,08	0,04
Equity ratio, %	53,2%	67,5%	40,1%
Share price at the end of the period, SEK	0,24	0,20	0,21
Number of shares at the end of the period	310 186 171	250 586 171	275 586 171
Average number of outstanding shares	305 572 838	250 586 171	266 103 979
Average number of employees	7	7	7
Number of employees at the end of the period	7	7	7

Definitions

Operating profit (EBIT)

Profit before financial items.

Earnings per share before dilution

Earnings per share before dilution is calculated by dividing profit attributable to the parent company's shareholders by the weighted average number of outstanding common shares during the period.

Equity per share

Equity at the end of the period divided by the number of shares outstanding at the end of the period.

Equity ratio

Equity as a percentage of total assets.

Average number of employees

Average number of employees during the period converted to full-time positions.

Financial overview

THE GROUP

TURNOVER AND RESULTS, JANUARY-MARCH 2025

Net revenue for the quarter amounted to 1,318 TSEK (3,410), with the majority now consisting of recurring license revenues. This marks a clear shift in the business model from the previous year when revenue was primarily driven by hardware sales. This change reflects the increased activation rate among our partners and demonstrates that previously delivered Dosell units are now generating recurring revenue as they are put into use within healthcare operations. Growth is occurring across several of our key markets and forms the foundation for our scalable and profitable revenue model.

Other operating income for the quarter amounted to 406 TSEK (396), primarily related to the subleasing of part of the company's premises.

Cost of goods sold for the quarter amounted to -1,010 TSEK (-4,042), primarily related to the costs of sold and delivered Dosell units as well as adjustments connected to inventory changes.

Other external costs for the quarter amounted to -1,213 TSEK (-2,111), including ongoing commercialization costs and continuous product improvements for Dosell. The company is actively optimizing its cost structure and procurement processes, which is now yielding results – other external costs have decreased by nearly 50%, equivalent to approximately 900 TSEK, compared to the same quarter last year.

Personnel costs for the quarter amounted to -2,035 TSEK (-2,238). The number of employees at the end of the period remained unchanged at 7. The reduction in costs reflects our focus on operational efficiency and resource optimization without compromising competence or the ability to drive growth.

Depreciation of intangible assets amounted to -714 TSEK (-714), related to capitalized development expenses for Dosell. Depreciation of tangible assets amounted to -267 TSEK (-267), relating to right-of-use assets and equipment.

Net financial items for the quarter amounted to -260 TSEK (-40), primarily due to interest on the loan raised in 2024. This item also includes interest expenses related to lease liabilities and deferred tax payments.

Tax on the period's result amounted to 0 TSEK (0), where the comparative year included the reversal of deferred tax related to goodwill from the acquisition of Pilloxa.

The net result for the period amounted to -3,779 TSEK (-5,609). Earnings per share amounted to -0.01 SEK (-0.02).



FINANCIAL POSITION, CASH FLOW AND LIQUIDITY

Cash flow from operating activities for the quarter amounted to -7,013 TSEK (-4,109), primarily explained by payments related to previously recognized and prepaid hardware deliveries to the Dutch market.

Cash flow from investing activities for the quarter amounted to -120 TSEK (-346), mainly attributable to intangible investments aimed at modernizing Dosell. This development work is intended to make the product compatible with newer technologies and prepare for broader market adaptation.

Cash flow from financing activities for the quarter amounted to 5,701 TSEK (-251), including repayments of lease liabilities and deferred tax payments. The positive development compared to the previous year is mainly due to the proceeds from the first tranche of the directed share issue completed during the quarter, which strengthened the company's financial position and enables continued investment in growth.

Cash and cash equivalents at the end of the period amounted to 718 TSEK, compared to 2,150 TSEK as of December 31, 2024. The decrease is primarily due to investments in production and adjustments to support expansion into new markets and attract more customers. These strategic initiatives are expected to strengthen the company's future revenue streams and position across several European markets.

It is also important to note that only half of the previously communicated directed share issue of approximately 9.2 MSEK had been received by the company at the end of the quarter. The remaining portion is expected during the coming quarter, which will further strengthen liquidity and improve the conditions for driving the company's growth strategy.

INVESTMENTS AND DEVELOPMENT EXPENDITURE


Investments during the quarter amounted to 120 TSEK (346), primarily related to capitalized development costs. The company has invested in platforms to enable increased sales in additional markets. At the same time, development of Dosell has continued, focusing on strengthening the product's capabilities and market adaptation. Investments for Dosell 3.0 are primarily being capitalized.

CONTINUING OPERATIONS

The company's ability to meet future liquidity needs is largely dependent on its sales performance and profitability. With the current liquid assets, implemented cost savings, and revenues from future agreements, the company's liquidity for the next 12 months is secured. The Board therefore assesses that, at the time of this report, there is no uncertainty regarding the company's continued operations. However, it should be noted that there are no guarantees that the company will be able to secure additional necessary liquidity if required.

PARENT COMPANY

In the parent company, group-wide functions are conducted, and the CEO as well as parts of the management team are employed in this company. The parent company has invoiced the subsidiary companies for management fees, which are eliminated at the group level.



Condensed income statement

GROUP

TSEK	2025	2024	2024
	Jan-Mar	Jan-Mar	Jan-Dec
Operating income			
Net sales	1 318	3 410	7 954
Other operating income	406	396	1 602
Total revenue	1 724	3 806	9 556
Operating costs			
Goods for resale	-1 010	-4 042	-9 588
Other external expenses	-1 213	-2 111	-6 803
Personell costs	-2 035	-2 238	-8 522
Depreciation of tangible and intangible assets	-981	-981	-3 930
Other operating expenses	-4	-3	-138
Other costs	-5 243	-9 375	-28 981
Operating profit/loss	-3 519	-5 569	-19 425
Net financial items	-260	-40	-1 084
Profit/loss after financial items	-3 779	-5 609	-20 509
Tax on profit for the period	0	0	0
PROFIT/LOSS FOR THE PERIOD	-3 779	-5 609	-20 509
Basic earnings per share (SEK)	-0,01	-0,02	-0,08

Condensed statement of financial position

GROUP

TSEK	2025 31-Mar	2024 31-Mar	2024 31-Dec
ASSETS			
Non-current assets			
Balanced development expenditure	15 818	17 823	16 405
Goodwill	19	45	26
Other intangible assets	31	127	47
Tangible fixed assets	754	2 159	1 005
Right-of-use assets	1 257	2 661	2 410
Current assets			
Inventories	2 802	3 704	2 966
Accounts receivable	628	3 662	589
Current receivable	2 812	795	1 042
Cash and cash equivalents	718	1 084	2 150
Total assets	23 582	29 399	24 230
SHAREHOLDERS' EQUITY AND LIABILITIES			
Shareholders' equity			
Share capital	62 037	50 117	55 117
Other capital contributions	130 535	131 071	130 867
Retained earnings including profit/loss for the period	-180 035	-161 356	-176 256
Total shareholders' equity	12 537	19 832	9 728
Non-current liabilities			
Interest-bearing liabilities	0	372	0
Lease liabilities	0	1 219	0
Current liabilities			
Interest-bearing liabilities	5 217	0	5 843
Lease liabilities	824	1 048	1 084
Accounts payable	1 409	4 842	3 510
Other current liabilities	3 595	2 086	4 065
Total liabilities	11 045	9 567	14 502
Total equity and liabilities	23 582	29 399	24 230

Condensed statement of changes in equity

GROUP

TSEK	2025	2024	2024
	Jan-Mar	Jan-Mar	Jan-Dec
Equity, opening balane	9 728	25 353	25 353
Total result			
The result of the period	-3 779	-5 609	-20 509
Transactions with owners			
New share issue	6 920	0	5 000
Issue with warrent rights	-332	0	-204
Share issue expenses	0	88	88
Warrent rights, paid premium	12 537	19 832	9 728
Equity, closing balance	15 636	42 741	15 636

Condensed statement of cash flows

GROUP

TSEK	2025	2024	2024
	Jan-Mar	Jan-Mar	Jan-Dec
Operating profit/loss	-3 519	-5 569	-19 425
Adjustments for non-cash items	981	981	4 242
Interest received, etc.	0	0	39
Interest paid, etc.	-260	-40	-1 123
Tax paid	0	0	0
Cash flow from operating activities before change in working capital	-2 798	-4 628	-16 267
Cash flow form changes in working capital	-4 215	519	4 912
Cash flow from operating activities	-7 013	-4 109	-11 355
Cash flow from investment activities	-120	-346	-1 023
Cash flow from financing activities	5 701	-295	8 694
Cash flow for the period	-1 432	-4 750	-3 684
Cash and cash equivalents at the beginning of the period	2 150	5 834	5 834
Cash and cash equivalents at close of period	718	1 084	2 150

Distribution of revenues

TSEK	2025	2024	2024
	Jan-Mar	Jan-Mar	Jan-Dec
Dosell	1 251	3 309	7 628
Pilloxa	67	101	326
Total	1 318	3 410	7 954

Reporting by business segment

TSEK	2025 Jan-Mar	2024 Jan-Mar	2024 Jan-Dec
External revenue			
Dosell	1 251	3 309	7 628
Pilloxa	67	101	326
	1 318	3 410	7 954
Direct costs			
Dosell	-1 010	-4 042	-9 588
Pilloxa	0	0	0
	-1 010	-4 042	-9 588
Contribution margin			
Dosell	241	-733	-1 960
Pilloxa	67	101	326
	308	-632	-1 634
Other items			
Other operating income	406	396	1 602
Other external costs	-1 217	-2 114	-6 941
Personnel costs	-2 035	-2 238	-8 522
	-2 846	-3 956	-13 861
Operating profit before depreciation	-2 538	-4 588	-15 495

Condensed income statement

PARENT COMPANY

TSEK	2025	2024	2024
	Jan-Mar	Jan-Mar	Jan-Dec
Operating income			
Net sales	450	450	1 809
Other operating income	401	396	1 586
Total revenue	851	846	3 395
Operating costs			
Other external expenses	-919	-1 241	-4 372
Personnel costs	-907	-934	-3 279
Depreciation and amortization of property, plant and equipment, and intangible assets	-12	-12	-50
Total costs	-1 838	-2 187	-7 701
Operating profit/loss	-987	-1 341	-4 306
Net financial items	-496	0	-10 076
Profit/loss after financial items	-1 483	-1 341	-14 382
Tax on profit for the period	0	0	0
PROFIT/LOSS FOR THE PERIOD	-1 483	-1 341	-14 382

Condensed balance sheet

PARENT COMPANY

TSEK	2025 31-Mar	2024 31-Mar	2024 31-Dec
ASSETS			
Non-current assets			
Property, plant and equipment	29	79	41
Non-current financial assets	34 995	32 000	34 675
Current assets			
Current receivables	5 125	4 970	764
Cash and bank balances	552	866	408
Total assets	40 701	37 915	35 888
SHAREHOLDERS' EQUITY AND LIABILITIES			
Restricted equity			
Share capital	62 037	50 117	55 117
Unrestricted equity			
Share premium reserve	130 093	130 628	130 425
Retained earnings including profit/loss for the period	-158 990	-144 467	-157 507
Total shareholders' equity	33 140	36 278	28 035
Current liabilities			
Liabilities to credit institutions	5 000	0	5 500
Accounts payable	891	483	768
Other current liabilities	1 670	1 154	1 585
Total liabilities	7 561	1 637	7 853
Total equity and liabilities	40 701	37 915	35 888

Accounting principles, risks, and other information.

NOTE 1. COMPANY INFORMATION

The group's operations include the development and marketing of products that contribute to a more qualitative and secure healthcare at home, both in the Swedish and international markets. The group develops and sells the product Dosell, with the aim of promoting reliable and safe medication management, and engages in the development and sales of the medical device, the connected pillbox Pilloxa, to improve medication adherence.

The parent company of the group, iZafe Group AB (org. no. 556762-3391), is a public limited company headquartered in Stockholm, Sweden. The company's B-shares are listed on the Nasdaq First North Growth Market. iZafe Group AB has two wholly-owned subsidiaries, the subsidiary Dosell AB (org. no. 556898-3018) and the subsidiary Pilloxa AB (org. no. 559019-3354).

In this report, iZafe Group AB (publ) is referred to either by its full name or as the parent company, and the iZafe group is referred to as iZafe or the group. All amounts are expressed in TSEK unless otherwise stated.

NOTE 2. PRINCIPLES FOR PREPARING THE INTERIM REPORT

The Group applies the Swedish Annual Accounts Act and the International Financial Reporting Standards (IFRS) as adopted by the EU, as well as RFR 1 Supplementary Accounting Rules for Groups when preparing financial reports. The parent company applies the Swedish Annual Accounts Act and RFR 2 Accounting for Legal Entities when preparing financial reports. This quarterly report has been prepared in accordance with IAS 34 Interim Financial Reporting. For detailed information on the company's accounting policies, please refer to the latest published annual report.

Changes to significant accounting policies

Several new standards and changes to standards will come into effect for financial years beginning on 1 January 2024. None of these are expected to have an impact on the Group's financial reports.

NOTE 3. TRANSACTIONS WITH RELATED PARTIES

The company's board has invoiced consulting services from related companies amounting to 0 TSEK (0) for the quarter. In addition to this, the group has not conducted any transactions with related parties during the reporting period other than customary salaries and compensations to the corporate management.

NOTE 4. FINANCIAL RISKS

Through its operations, iZafe is exposed to several financial risks, such as market risk, credit risk, currency risk, and liquidity risk. The group's management and board actively work to minimize these risks. A detailed account of these risks is provided in the latest published annual report.



NOTE 5. SIGNIFICANT RISKS AND UNCERTAINTIES

The group's operations consist of selling the patented medication robot Dosell along with associated subscription fees. Dosell has recently been launched on the market. Therefore, it is not yet possible to draw far-reaching conclusions about the market's acceptance of the product or observe any trends in sales and profitability. Furthermore, the company relies on intellectual property rights that are difficult to protect through registration. The developed technical platform for Pilloxa follows the same risk pattern as Dosell, given that the company is relatively young.

The company's ability to cover future liquidity needs largely depends on its sales results and profitability. With current liquid assets, cost savings, and revenues from future contracts, the company's liquidity for the next 12 months is secured. Therefore, the board assesses that, at the time of this report, there is no uncertainty regarding the company's ongoing operations. However, it should be noted that there are no guarantees that the company can secure additional necessary liquidity if needed.

NOTE 6. SEGMENTS

The Group operates in two segments: Dosell and Pilloxa.

NOTE 7. IZAFE SHARES

iZafe has issued two classes of shares, A-shares and B-shares. The B-share is traded on the Nasdaq First North Growth Market.

Each A-share carries ten votes per share, while each B-share carries one vote per share. As of September 30, 2024, the share capital amounted to 55,117,234 SEK, divided into 600,000 A-shares and 274,986,171 B-shares, with a nominal value of 0.2 SEK per share.

NOTE 8. OPTIONS AND CONVERTIBLE LOAN

The group has three outstanding stock option programs.

TO11 - Incentive program for certain employees

Each TO11 option entitles the holder to subscribe for one (1) new Series B share in the Company against cash payment equivalent to 200 percent of the volume-weighted average price according to Nasdaq's official stock exchange list for shares during the 10 trading days immediately preceding the extraordinary general meeting. The subscription price is therefore SEK 0.88. Subscription for the shares under the option terms shall be made during the period from November 1, 2025 to November 30, 2025. The total number of options in TO11 is 1,700,000.

Upon full exercise, the share capital will increase by SEK 340,000. The options are subject to customary adjustment conditions in connection with issuances, etc.

TO12 - Incentive Program for Board Members

Each option of series TO12 entitles the holder to subscribe for one (1) new B-share in the Company against cash payment corresponding to 200 percent of the volume-weighted average price according to Nasdaq's official price list for the shares during the 10 trading days immediately preceding the extraordinary general meeting. The subscription price is thus 0.88 SEK. The subscription of shares under the option program is to be made in accordance with the terms of the options during the period from November 1, 2025, to November 30, 2025. The total number of options in TO12 is 2,900,000.

Upon full exercise, the share capital will increase by 580,000 SEK. The options are subject to customary adjustment conditions in connection with share issues, etc.

LTIP 2023 - Incentive Program for CEO, Executives, and Other Employees

LTIP 2023 comprises three series of options for the Company's CEO, executives, and other employees. Participants are offered to acquire an equal number of options of each series. LTIP 2023 comprises a total of approximately 7,900,000 options, which together entitle the holder to subscribe for a maximum of approximately 13,180,000 B-shares.

Each series of options entitles the holder to subscribe for B-shares in the Company at the par value of the B-share of 0.20 SEK per B-share, subject to a certain share price for the Company's B-share on Nasdaq First North Growth Market (or another trading venue in the event of a listing change) has been achieved as the average closing price for the ten trading days preceding the first day of exercise of the options. Upon full exercise, the share capital will increase by approximately 2,636,000 SEK. The options are subject to customary adjustment conditions in connection with share issues, etc. The number of B-shares that each series entitles to subscribe for, the subscription period, and the Share Price Target for each series are specified below.

Series	Total number of options per series	B shares per option upon exercise	Share price target	Exercise price per B share at the achievement of the Share Price Target	Exercise period
A	2,635,959	2	250%	Par value (0.20 kr)	1–31 December 2025
B	2,635,959	2	375%	Par value (0.20 kr)	1–31 December 2025
C	2,635,959	1	500%	Par value (0.20 kr)	1–31 December 2025

Convertible Loan

iZafe Group AB entered into a loan agreement of 5 MSEK with Exelity AB during the quarter. The loan is due for repayment on June 30, 2025. The lender has the right to convert the loan into shares in the company at any time during the term at a subscription price of 0.24 SEK per share

In addition to the aforementioned option program, there are currently no other outstanding warrants, convertibles, or similar financial instruments that may entitle the subscription of new shares or otherwise affect the share capital of the company.

The maximum dilution effect of the option programs amounts to approximately 11,6% of the total number of shares and votes in the company.

AUDIT REVIEW

This report has not been subject to review by the auditor of iZafe Group.

CERTIFIED ADVISER

Carnegie Investment Bank AB

UPCOMING FINANCIAL REPORTS

2025-04-30	2024 Annual report
2025-05-28	Annual General Meeting
2025-08-30	2025 Interim report Q2
2025-11-03	2025 Interim report Q3
2026-02-16	2025 Year-End Report

Financial reports are available on the company's website, www.izafegroup.com, the same day as they are published.

DECLARATION

The Board of Directors and the CEO confirm that the interim report provides a true and fair overview of the parent company's and the Group's operations, position, and results, as well as describes the significant risks and uncertainties facing the parent company and the companies included in the Group.

Stockholm, April 25, 2025.

iZafe Group AB (publ.)

Anders Segerström	CEO
Richard Wolff	Chairman of the Board
Göran Hermansson	Vice Chairman of the Board
Magnus Engman	Board Member
Jenny Styren	Board Member

CONTACT



- 📍 iZafe Group AB
David bagares gata 3, 111 38 Stockholm
- ✉ info@izafegroup.com
- ☎ +46 821 11 21
- 🌐 www.izafegroup.com